Sequitur, Inc. (Acquired By Invitrogen)

14 Tech Circle
Natick
Massachusetts
01760
United States

Tel: 508-650-1459
Fax: 508-655-1625

Email: support@SequiturInc.com

Show jobs for this employer

About Sequitur, Inc. (Acquired By Invitrogen)

Sequitur, Inc. was founded in 1996 to develop innovative sequence-based compounds for functional genomics research, diagnostic, and therapeutic applications. Sequitur's proprietary antisense technology can be employed to determine gene function and validate small molecule targets by specifically inhibiting gene expression. We also offer a line of products and services relating to gene expression and gene detection. Research is performed in our recently renovated state-of-the-art GLP cellular and molecular biology laboratory space in Natick, Massachusetts. Sequitur's scientific advisory board includes leaders in the fields of oligonucleotide and gene therapy research. Sequitur provides services in the following interrelated areas:
ANTISENSE FUNCTIONAL GENOMICS PROGRAM Based upon a yearly licensing fee, a corporate client obtains non-exclusive research use of Sequitur's current and newly developed functional genomics technology. Sequitur has one issued patent and five patents pending in the field of oligonucleotide technology. Research agreements are also available for Sequitur to experimentally determine optimal antisense sites within target genes.
HIGH THROUGHPUT ONE STEP TARGET DISCOVERY AND VALIDATION Omniscreen™ is a modification of the current method of discovering and validating targets. The current method is restricted to identification of genes upregulated in disease states and requires years of research. This old method is replaced by Omniscreen ™ which applies a library of antisense oligos to targets using high throughput cell culture disease model screens.
Last Updated 7-24-01

1 article about Sequitur, Inc. (Acquired By Invitrogen)